Clinical Scorecard: Exploring Androgenetic Alopecia in Transgender and Gender-Diverse Populations: Insights on Characterization and Treatment Approaches

At a Glance

Key Highlights

• AGA can exacerbate gender dysphoria and impact quality of life.
• Oral minoxidil is recommended for all individuals with AGA.
• Adjunctive treatments like dutasteride or finasteride may be considered for transgender men.
• Spironolactone is a first-line antiandrogen for transgender women.
• Individualized treatment plans are essential based on personal therapeutic goals.

Guideline-Based Recommendations

Diagnosis

• Timely recognition of AGA in TGD individuals is crucial.

Management

• Oral minoxidil should be considered for all individuals.
• Higher doses of oral minoxidil may be used in transgender men for beard and body hair growth.
• Consider adjunctive treatments like dutasteride or finasteride in transgender men.

Monitoring & Follow-up

• Monitor for side effects and treatment efficacy, especially with hormonal therapies.

Risks

• Careful evaluation of 5-alpha reductase inhibitors in individuals with suppressed testosterone levels.

Patient & Prescribing Data

Transgender and gender-diverse individuals experiencing AGA.

Treatment should be individualized based on developmental stage and specific treatment goals.

Clinical Best Practices

• Provide culturally competent and gender-affirming care.
• Consider age, prior treatments, and individual anatomy when managing AGA.
• Utilize evidence from both TGD and cisgender studies to inform treatment decisions.

References

• Source Article